China Grants Breakthrough Therapy Designation to CSPC's EGFR ADC in AGA-Negative NSCLC
核心洞察
China's NMPA has granted Breakthrough Therapy Designation to SYS6010, CSPC's EGFR (搜索)-targeted antibody-drug conjugate, for recurrent or metastatic AGA-negative non-squamous NSCLC after immunotherapy and platinum chemotherapy.
CSPC says the AGA-negative population represents roughly 40% of NSCLC cases in China and has limited options beyond single-agent chemotherapy after first-line failure.
SYS6010 pairs a humanised anti-EGFR (搜索) antibody with a topoisomerase I inhibitor payload via a cleavable linker, and a randomised Phase III monotherapy trial in this setting is enrolling.
CSPC Pharmaceutical Group (搜索) announced that China's National Medical Products Administration (搜索) has granted Breakthrough Therapy Designation to SYS6010, an EGFR (搜索)-targeted antibody-drug conjugate, for recurrent or metastatic actionable genomic alteration (AGA)-negative non-squamous non-small cell lung cancer (搜索) that has progressed on prior immunotherapy and platinum-based chemotherapy. According to CSPC, this population accounts for approximately 40% of all NSCLC cases in China, and after first-line failure has limited options beyond single-agent chemotherapy, which the company said delivers suboptimal response rates and modest survival benefits.
SYS6010 consists of a humanised anti-EGFR (搜索) monoclonal antibody conjugated to a topoisomerase I inhibitor payload through a cleavable linker. The construct binds EGFR on tumour cell surfaces and releases its cytotoxic payload upon internalisation. CSPC reported that in AGA-negative non-squamous NSCLC the drug produced progression-free survival more than twice that of standard treatment and a durable objective response, though response rate figures and patient numbers were not disclosed. A randomised, open-label, multicentre Phase III trial comparing SYS6010 monotherapy with investigator-selected chemotherapy in AGA-negative locally advanced or metastatic non-squamous NSCLC that has failed standard treatment is enrolling.
The designation is the fourth CSPC has received for SYS6010 in China. Earlier designations covered EGFR (搜索) mutation-positive NSCLC after failure of EGFR tyrosine kinase inhibitors and platinum-based chemotherapy; unresectable locally advanced or metastatic oesophageal squamous cell carcinoma (搜索) after first-line platinum-based chemotherapy and immune checkpoint inhibitors; and recurrent or metastatic head and neck squamous cell carcinoma (搜索) after immunotherapy and platinum-based chemotherapy. The AGA-negative NSCLC setting is also being targeted by Daiichi Sankyo and AstraZeneca's TROP2 (搜索)-directed ADC datopotamab deruxtecan, which is being compared with docetaxel in the Phase III TROPION-Lung17 study in previously treated, TROP2 NMR-positive non-squamous NSCLC without actionable genomic alterations.